YIH
MLTX icon

Y-Intercept (HK)’s MoonLake Immunotherapeutics MLTX Stock Holding History

Y-Intercept (HK)’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.2M Buy
215,849
+88,762
+70% +$1.61M 0.08% 337
2026
Q1 		$2.37M Buy
127,087
+31,115
+32% +$515K 0.04% 641
2025
Q4 		$1.26M Buy
+95,972
New +$1.13M 0.03% 865
2025
Q1 		– Sell
-9,229
Closed -$500K – 1458
2024
Q4 		$500K Sell
9,229
-11,096
-55% -$567K 0.03% 726
2024
Q3 		$1.02M Buy
20,325
+7,247
+55% +$340K 0.06% 440
2024
Q2 		$575K Buy
+13,078
New +$554K 0.03% 750
2024
Q1 		– Sell
-11,227
Closed -$678K – 1611
2023
Q4 		$678K Buy
+11,227
New +$579K 0.06% 468

Other funds holding MLTX

CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Y-Intercept (HK)'s MLTX Position: Q2 2026 in Review

Y-Intercept (HK) increased its MoonLake Immunotherapeutics (MLTX) stake by 70% in Q2 2026, buying an estimated $1.61M and bringing the position to 215,849 shares worth $4.2M. The position accounts for 0.08% of the portfolio, ranked #337.

Y-Intercept (HK) first reported a position in MLTX in Q4 2023 and has held it in 7 quarters since. 6 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Y-Intercept (HK) held 215,849 shares of MoonLake Immunotherapeutics worth $4.2M as of Q2 2026.
  • Y-Intercept (HK) bought 88,762 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $1.61M.
  • MoonLake Immunotherapeutics made up 0.08% of Y-Intercept (HK)'s portfolio in Q2 2026, its #337 holding.
  • Y-Intercept (HK) first reported a position in MoonLake Immunotherapeutics in Q4 2023 and has held it in 7 quarters since.
  • 6 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.